JADRAN - GALENSKI LABORATORIJ D.D. financials
JADRAN - GALENSKI LABORATORIJ D.D.
Country: HR Reporting currency: EUR Latest annual report: 2024-12-31
LEI:
529900NRAH6YWL3TLD24 Financial statements
(EUR, as reported — unscaled; 101 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €246.1M | €208.2M |
| Other income | €3.5M | €2.7M |
| Operating expenses | €216.3M | €183.9M |
| Employee benefits expense | €45.8M | €36.9M |
| Depreciation & amortisation | €11.6M | €9.9M |
| Net finance income / (cost) | -€4.6M | -€5.6M |
| Finance costs | €6.6M | €7.8M |
| Profit before tax | €28.8M | €21.4M |
| Income tax expense | €2.2M | €1.8M |
| Profit for the year | €26.6M | €19.6M |
| Total comprehensive income | €25.6M | €19.1M |
| Per share | ||
| Basic EPS | €21.59 | €16.41 |
| Diluted EPS | €21.59 | €16.41 |
| Free cash flow / share | €6.90 | €0.37 |
| Cash flow statement | ||
| Net cash from operating activities | €15.7M | €17.4M |
| Income taxes paid | €329.0K | €243.3K |
| Net cash from investing activities | -€6.2M | -€17.6M |
| Net cash from financing activities | €30.4M | €6.7M |
| Dividends paid | €4.9M | €3.6M |
| Proceeds from borrowings | €3.6M | €15.6M |
| Repayments of borrowings | €27.2M | €6.4M |
| Lease liability payments | €2.5M | €2.6M |
| Balance sheet | ||
| Total assets | €339.6M | €273.7M |
| Non-current assets | €147.0M | €146.6M |
| Property, plant & equipment | €111.9M | €116.3M |
| Intangible assets & goodwill | €26.3M | €23.9M |
| Current assets | €192.5M | €127.1M |
| Inventories | €57.4M | €46.4M |
| Trade & other receivables | €69.7M | €53.3M |
| Cash & equivalents | €60.7M | €20.9M |
| Total equity | €161.3M | €139.4M |
| Non-current liabilities | €119.7M | €66.4M |
| Lease liabilities (non-current) | €4.6M | €4.6M |
| Current liabilities | €58.6M | €67.9M |
| Lease liabilities (current) | €2.5M | €2.5M |
| Deferred tax liabilities | €1.4M | €838.6K |
| Derived metrics | ||
| Free cash flow | €8.5M | €442.1K |
| Net margin | 10.8% | 9.4% |
| Return on equity | 16.5% | 14.0% |
| Cash conversion ratio | 0.59× | 0.89× |
| Capex coverage | 2.18× | 1.03× |
| Other reported items | ||
| Cash Advances and Loans Made To Other Parties Classified As Investing Activities | €0 | €32.0K |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €0 | €0 |
| Cash Receipts From Repayment of Advances and Loans Made To Other Parties Classified As Investing Activities | €12.7K | €26.5K |
| Changes In Inventories of Finished Goods and Work In Progress | -€788.1K | -€5.8M |
| Current Bonds Issued and Current Portion of Noncurrent Bonds Issued | €0 | €16.9M |
| Current Financial Assets At Fair Value Through Profit Or Loss | €3.0M | €2.9M |
| Current Loans Received and Current Portion of Noncurrent Loans Received | €7.0M | €6.4M |
| Current Tax Assets Current | €706.3K | €2.4M |
| Current Tax Liabilities Current | €199.1K | €85.2K |
| Deferred Tax Assets | €5.7M | €3.8M |
| Dividends Received Classified As Investing Activities | €0 | €0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €23.7K | -€50.2K |
| Equity and Liabilities | €339.6M | €273.7M |
| Finance Income | €2.0M | €2.1M |
| Gains Losses On Exchange Differences On Translation Net of Tax | -€982.2K | -€460.8K |
| Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €1.2M | €5.0M |
| Income Taxes Refund Classified As Operating Activities | €3.4M | €3.9M |
| Increase Decrease In Cash and Cash Equivalents | €39.8M | €6.5M |
| Increase Decrease Through Acquisition of Subsidiary | €103.0K | — |
| Increase Decrease Through Disposal of Subsidiary | -€218.1K | — |
| Increase Decrease Through Sharebased Payment Transactions | €504.3K | -€1.9M |
| Increase Decrease Through Transfers and Other Changes Equity | -€834.7K | €0 |
| Increase Decrease Through Treasury Share Transactions | -€480.3K | €4.0M |
| Inflows of Cash From Investing Activities | €1.7M | €744.7K |
| Interest Paid Classified As Operating Activities | €1.3M | €1.2M |
| Interest Received Classified As Investing Activities | €1.3M | €453.0K |
| Investment Property | €2.9M | €2.3M |
| Investments In Subsidiaries | €0 | €0 |
| Issue of Equity | €2.2M | €1.9M |
| Issued Capital | €16.6M | €16.3M |
| Noncurrent Payables To Trade Suppliers | €112 | €225 |
| Noncurrent Portion of Noncurrent Bonds Issued | €59.5M | €0 |
| Noncurrent Portion of Noncurrent Loans Received | €53.6M | €60.4M |
| Noncurrent Provisions | €642.2K | €582.8K |
| Other Cash Payments From Operating Activities | €33.0M | €25.9M |
| Other Cash Receipts From Operating Activities | €840.4K | €549.2K |
| Other Comprehensive Income | -€982.2K | -€460.8K |
| Other Current Assets | €1.1M | €1.0M |
| Other Current Financial Assets | €18.1K | €46.2K |
| Other Current Liabilities | €15.3M | €12.3M |
| Other Expense By Nature | €14.2M | €11.2M |
| Other Noncurrent Financial Assets | €282.1K | €271.7K |
| Other Reserves | €19.8M | €18.9M |
| Outflows of Cash From Investing Activities | €7.9M | €18.3M |
| Payments For Premiums and Claims Annuities and Other Policy Benefits | €614.0K | €395.2K |
| Payments To Acquire Or Redeem Entitys Shares | €480.3K | €14.1K |
| Payments To and On Behalf of Employees | €30.8M | €25.0M |
| Payments To Suppliers For Goods and Services | €166.5M | €149.2M |
| Proceeds From Disposals of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €360.0K | €247.9K |
| Proceeds From Issuing Shares | €274.4K | €276.5K |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €7.2M | €17.0M |
| Receipts From Premiums and Claims Annuities and Other Policy Benefits | €314.7K | €209.3K |
| Receipts From Sales of Goods and Rendering of Services | €243.6M | €214.7M |
| Retained Earnings Excluding Profit Loss For Reporting Period | €98.9M | €85.2M |
| Retained Earnings Profit Loss For Reporting Period | €26.6M | €19.6M |
| Revenue and Operating Income | €249.7M | €210.9M |
| Services Expense | €47.1M | €40.1M |
| Share of Profit Loss of Associates Accounted For Using Equity Method | €6.7K | €5.2K |
| Trade and Other Current Payables To Trade Suppliers | €33.6M | €29.6M |
| Treasury Shares | €523.3K | €532.6K |
Methodology
Every line item above is a fact tagged in JADRAN - GALENSKI LABORATORIJ D.D.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.